Vtv Therapeutics INC 8-K filings

vTv Therapeutics reported Q2 2026 financial results, highlighting progress in its Phase 3 CATT1 trial for type 1 diabetes and confirming operational funding through the anticipated topline data readout.

vTv Therapeutics Inc. announced the results of its 2026 Annual Meeting of Stockholders, including the election of directors and ratification of its independent auditor.

vTv Therapeutics has filed a prospectus supplement to increase the number of shares available under its existing at-the-market sales program.

vTv Therapeutics Inc. posted an updated investor presentation highlighting its lead asset, Cadisegliatin, in Phase 3 development for Type 1 Diabetes with topline data expected in 2H 2026.

vTv Therapeutics' subsidiary, vTv LLC, amended its license agreement with Newsoara Biopharma, expanding global rights for its PDE4 inhibitor HPP737 for an upfront payment of $20 million and potential milestones up to $115 million plus royalties.

vTv Therapeutics Inc. amended its by-laws, reducing the quorum requirement for stockholder meetings to 33.4%.

vTv Therapeutics reported Q3 2025 financial results, highlighted by an $80 million private placement and progress in its Phase 3 CATT1 trial for type 1 diabetes.

vTv Therapeutics Inc. announced its participation in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference on September 10, 2025.

vTv Therapeutics Inc. has successfully raised approximately $80 million in a private placement to fund the continued clinical development of its products, including cadisegliatin.

vTv Therapeutics announced its second quarter 2025 financial results and provided a corporate update, including the randomization of the first participant in its Phase 3 CATT1 trial for cadisegliatin.

vTv Therapeutics Inc. announced the successful election of its seven director nominees and the ratification of Ernst & Young LLP as its independent registered public accounting firm at its 2025 Annual Meeting of Stockholders.

vTv Therapeutics appoints Michael Tung as CFO and reinitiates its Phase 3 trial for cadisegliatin, an oral adjunctive therapy for type 1 diabetes.

vTv Therapeutics presents an investor update focusing on Cadisegliatin, a potential first-in-class oral adjunct therapy for Type 1 Diabetes, with Phase 3 data expected in the second half of 2026.

vTv Therapeutics reports Q1 2025 financial results and provides an update on the Phase 3 trial of cadisegliatin for type 1 diabetes, with topline data expected in the second half of 2026.

vTv Therapeutics Inc. has appointed Barry K. Brown as interim principal financial officer, effective immediately, while the company continues its search for a permanent CFO.

vTv Therapeutics announces the lifting of a clinical hold and the expected resumption of the Phase 3 CATT1 trial for Cadisegliatin in Q2 2025, aiming to improve glycemic control in Type 1 Diabetes patients.

vTv Therapeutics reports its Q4 and full-year 2024 financial results, highlights the lifting of the clinical hold on its cadisegliatin program, and announces a new Chief Commercial Officer.

The FDA has lifted the clinical hold on vTv Therapeutics' cadisegliatin program for diabetes, paving the way for the resumption of the CATT1 Phase 3 trial.

Steven Tuch, Executive Vice President and CFO of vTv Therapeutics, will resign effective March 21, 2025.

vTv Therapeutics has released an updated investor presentation highlighting the development of their lead drug candidate, cadisegliatin, for type 1 diabetes and other pipeline programs.

vTv Therapeutics announced its third quarter 2024 financial results, highlighting a strengthened cash position and progress in its cadisegliatin program despite an ongoing clinical hold.

vTv Therapeutics' subsidiary, vTv LLC, received notice from OnKure Therapeutics of their intent to terminate the license agreement for the PPAR-delta agonist program, effective January 20, 2025.

vTv Therapeutics reported its second quarter 2024 financial results, highlighted by progress in its clinical programs and a global licensing agreement expansion.

The FDA has placed a clinical hold on vTv Therapeutics' cadisegliatin program for type 1 diabetes due to an unresolved chromatographic signal found in a recent study.

vTv Therapeutics has amended its licensing agreement with Newsoara Biopharma, potentially securing up to $96 million in upfront and milestone payments, plus royalties.

vTv Therapeutics held its 2024 Annual Meeting of Stockholders on June 11, 2024, where directors were elected, a new equity incentive plan was approved, and the company's independent auditor was ratified.

vTv Therapeutics announced its first quarter 2024 financial results, highlighting a strengthened balance sheet and progress in its clinical development program for cadisegliatin.

vTv Therapeutics has been notified by Nasdaq that it has regained compliance with the minimum market value of listed securities requirement, allowing its stock to continue trading on the Nasdaq Capital Market.

vTv Therapeutics has appointed Anne Phillips as a new director, effective upon the filing of their 2023 Annual Report, while also seeing the departure of two existing directors.

vTv Therapeutics reported its 2023 financial results, highlighted by a $51 million private placement and the upcoming Phase 3 trial for its lead drug candidate, cadisegliatin.